TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
GLP-1 & Metabolic Drugs · FDA compounding pathway opens for therapeutic peptides beyond GLP-1s
now playing · GLP-1 & Metabolic Drugs
GLP-1 & Metabolic Drugstailwindscore 7/10travis holly
FDA compounding pathway opens for therapeutic peptides beyond GLP-1s
FDA advisory panel recommendations to allow compounding of peptides like BPC-157 and KPV create a new regulatory pathway for affordable peptide therapies, enabling platforms like Hims & Her…
Healthcare Systems & Policytailwindscore 6/10travis holly
Compounding pharmacy regulatory shift enables direct-to-consumer peptide access
The FDA's review of peptide compounding eligibility represents a structural policy shift that could legitimize direct-to-consumer peptide therapies outside traditional insurance reimburseme…
AI in Healthcaretailwindscore 6/10travis holly
Hims & Hers builds AI-driven personalized care flywheel from lab data
Hims & Hers is shifting from transactional prescriptions to an AI-powered platform where lab data feeds conversational AI and providers to create personalized, compounded treatment plans wi…